Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Early central vs. peripheral immunological and neurobiological effects of fingolimod-a longitudinal study.

Sehr T, Akgün K, Proschmann U, Bucki R, Zendzian-Piotrowska M, Ziemssen T.

J Mol Med (Berl). 2019 Jun 26. doi: 10.1007/s00109-019-01812-x. [Epub ahead of print]

PMID:
31243520
2.

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS.

Akgün K, Kretschmann N, Haase R, Proschmann U, Kitzler HH, Reichmann H, Ziemssen T.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 8;6(3):e555. doi: 10.1212/NXI.0000000000000555. eCollection 2019 May.

3.

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting.

Rodriguez-Leal FA, Haase R, Akgün K, Eisele J, Proschmann U, Schultheiss T, Kern R, Ziemssen T.

Ther Adv Chronic Dis. 2019 Apr 19;10:2040622319835136. doi: 10.1177/2040622319835136. eCollection 2019.

4.

Letter to the editor regarding "Therapeutic drug monitoring of natalizumab".

Proschmann U, Sehr T, Akgün K, Ziemssen T.

Mult Scler. 2019 Apr 3:1352458519837702. doi: 10.1177/1352458519837702. [Epub ahead of print] No abstract available.

PMID:
30943104
5.

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up.

Kaufmann M, Haase R, Proschmann U, Ziemssen T, Akgün K.

Front Neurol. 2018 Dec 7;9:1071. doi: 10.3389/fneur.2018.01071. eCollection 2018.

6.

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients.

Kaufmann M, Haase R, Proschmann U, Ziemssen T, Akgün K.

Front Immunol. 2018 Nov 20;9:2669. doi: 10.3389/fimmu.2018.02669. eCollection 2018.

7.

Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Proschmann U, Akgün K, Ziemssen T.

Neurology. 2018 Oct 30;91(18):849-850. doi: 10.1212/WNL.0000000000006422. No abstract available.

PMID:
30373924
8.

Natalizumab during pregnancy and lactation.

Proschmann U, Thomas K, Thiel S, Hellwig K, Ziemssen T.

Mult Scler. 2018 Oct;24(12):1627-1634. doi: 10.1177/1352458517728813. Epub 2017 Aug 31.

PMID:
28857686
9.

Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.

Thomas K, Proschmann U, Ziemssen T.

Expert Opin Pharmacother. 2017 Oct;18(15):1649-1660. doi: 10.1080/14656566.2017.1373093. Epub 2017 Sep 4. Review.

PMID:
28844164
10.

Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".

Sehr T, Proschmann U, Thomas K, Ziemssen T.

Mult Scler. 2018 May;24(6):820-822. doi: 10.1177/1352458517726384. Epub 2017 Aug 14. No abstract available.

PMID:
28805095
11.

Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?

Rodriguez-Leal FA, Haase R, Thomas K, Eisele JC, Proschmann U, Schultheiss T, Kern R, Ziemssen T.

Mult Scler. 2018 Sep;24(10):1337-1346. doi: 10.1177/1352458517720043. Epub 2017 Jul 25.

PMID:
28741976
12.

Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation.

Thomas K, Sehr T, Proschmann U, Rodriguez-Leal FA, Haase R, Ziemssen T.

J Neuroinflammation. 2017 Feb 23;14(1):41. doi: 10.1186/s12974-017-0817-6.

13.

New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.

Sehr T, Proschmann U, Thomas K, Marggraf M, Straube E, Reichmann H, Chan A, Ziemssen T.

J Neuroinflammation. 2016 Jun 27;13(1):164. doi: 10.1186/s12974-016-0635-2.

Supplemental Content

Loading ...
Support Center